Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP

  1. Jachimowicz, Ron D. ORCID logo
  2. Klapper, Wolfram ORCID logo
  3. Glehr, Gunther
  4. Müller, Horst
  5. Haverkamp, Heinz ORCID logo
  6. Thorns, Christoph
  7. Hansmann, Martin Leo
  8. Möller, Peter
  9. Stein, Harald
  10. Rehberg, Thorsten
  11. von Tresckow, Bastian
  12. Reinhardt, H. C.
  13. Borchmann, Peter
  14. Chan, Fong Chun
  15. Spang, Rainer
  16. Scott, David W.
  17. Engert, Andreas
  18. Steidl, Christian ORCID logo
  19. Altenbuchinger, Michael
  20. Rosenwald, Andreas

Download
s41375-021-01314-1.pdf 594,67KB
WeightNameValue
1000 Titel
  • Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP
1000 Autor/in
  1. Jachimowicz, Ron D. |
  2. Klapper, Wolfram |
  3. Glehr, Gunther |
  4. Müller, Horst |
  5. Haverkamp, Heinz |
  6. Thorns, Christoph |
  7. Hansmann, Martin Leo |
  8. Möller, Peter |
  9. Stein, Harald |
  10. Rehberg, Thorsten |
  11. von Tresckow, Bastian |
  12. Reinhardt, H. C. |
  13. Borchmann, Peter |
  14. Chan, Fong Chun |
  15. Spang, Rainer |
  16. Scott, David W. |
  17. Engert, Andreas |
  18. Steidl, Christian |
  19. Altenbuchinger, Michael |
  20. Rosenwald, Andreas |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-06-10
1000 Erschienen in
1000 Quellenangabe
  • 35(12):3589-3593
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1038/s41375-021-01314-1 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632672/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Persistence of malignant clones is a major determinant of adverse outcome in patients with hematologic malignancies. Despite the fact that the majority of patients with acute myeloid leukemia (AML) achieve complete remission after chemotherapy, a large proportion of them relapse as a result of residual malignant cells. These persistent clones have a competitive advantage and can re-establish disease. Therefore, targeting strategies that specifically diminish cell competition of malignant cells while leaving normal cells unaffected are clearly warranted. Recently, our group identified YBX1 as a mediator of disease persistence in JAK2-mutated myeloproliferative neoplasms. The role of YBX1 in AML, however, remained so far elusive. Here, inactivation of YBX1 confirms its role as an essential driver of leukemia development and maintenance. We identify its ability to amplify the translation of oncogenic transcripts, including MYC, by recruitment to polysomal chains. Genetic inactivation of YBX1 disrupts this regulatory circuit and displaces oncogenic drivers from polysomes, with subsequent depletion of protein levels. As a consequence, leukemia cells show reduced proliferation and are out-competed in vitro and in vivo, while normal cells remain largely unaffected. Collectively, these data establish YBX1 as a specific dependency and therapeutic target in AML that is essential for oncogenic protein expression.
1000 Sacherschließung
lokal Letter
lokal Cyclophosphamide/therapeutic use [MeSH]
lokal Receptor, Platelet-Derived Growth Factor alpha/genetics [MeSH]
lokal Etoposide/therapeutic use [MeSH]
lokal Neoplasm Staging [MeSH]
lokal Male [MeSH]
lokal Hodgkin Disease/genetics [MeSH]
lokal Ki-1 Antigen/metabolism [MeSH]
lokal Prednisone/therapeutic use [MeSH]
lokal Hodgkin Disease/pathology [MeSH]
lokal Adolescent [MeSH]
lokal Female [MeSH]
lokal Bleomycin/therapeutic use [MeSH]
lokal Hodgkin Disease/drug therapy [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Treatment Outcome [MeSH]
lokal Predictive Value of Tests [MeSH]
lokal Middle Aged [MeSH]
lokal Procarbazine/therapeutic use [MeSH]
lokal Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH]
lokal Survival Rate [MeSH]
lokal Ki-1 Antigen/genetics [MeSH]
lokal Young Adult [MeSH]
lokal Gene Expression Profiling/methods [MeSH]
lokal Vincristine/therapeutic use [MeSH]
lokal Receptor, Platelet-Derived Growth Factor alpha/metabolism [MeSH]
lokal Transcriptome [MeSH]
lokal Chemokine CCL17/genetics [MeSH]
lokal Chemokine CCL17/metabolism [MeSH]
lokal Cancer microenvironment
lokal Doxorubicin/therapeutic use [MeSH]
lokal Hodgkin lymphoma
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0001-9522-7061|https://orcid.org/0000-0001-7208-4117|https://frl.publisso.de/adhoc/uri/R2xlaHIsIEd1bnRoZXI=|https://frl.publisso.de/adhoc/uri/TcO8bGxlciwgSG9yc3Q=|https://orcid.org/0000-0001-6895-4132|https://frl.publisso.de/adhoc/uri/VGhvcm5zLCBDaHJpc3RvcGg=|https://frl.publisso.de/adhoc/uri/SGFuc21hbm4sIE1hcnRpbiBMZW8=|https://frl.publisso.de/adhoc/uri/TcO2bGxlciwgUGV0ZXI=|https://frl.publisso.de/adhoc/uri/U3RlaW4sIEhhcmFsZA==|https://frl.publisso.de/adhoc/uri/UmVoYmVyZywgVGhvcnN0ZW4=|https://frl.publisso.de/adhoc/uri/dm9uIFRyZXNja293LCBCYXN0aWFu|https://frl.publisso.de/adhoc/uri/UmVpbmhhcmR0LCBILiBDLg==|https://frl.publisso.de/adhoc/uri/Qm9yY2htYW5uLCBQZXRlcg==|https://frl.publisso.de/adhoc/uri/Q2hhbiwgRm9uZyBDaHVu|https://frl.publisso.de/adhoc/uri/U3BhbmcsIFJhaW5lcg==|https://frl.publisso.de/adhoc/uri/U2NvdHQsIERhdmlkIFcu|https://frl.publisso.de/adhoc/uri/RW5nZXJ0LCBBbmRyZWFz|https://orcid.org/0000-0001-9842-9750|https://frl.publisso.de/adhoc/uri/QWx0ZW5idWNoaW5nZXIsIE1pY2hhZWw=|https://frl.publisso.de/adhoc/uri/Um9zZW53YWxkLCBBbmRyZWFz
1000 Hinweis
  • DeepGreen-ID: f5811c0d8e0044fab1c7583dcb12b202 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6443816.rdf
1000 Erstellt am 2023-04-27T10:55:32.251+0200
1000 Erstellt von 322
1000 beschreibt frl:6443816
1000 Zuletzt bearbeitet Sat Oct 14 11:27:59 CEST 2023
1000 Objekt bearb. Sat Oct 14 11:27:59 CEST 2023
1000 Vgl. frl:6443816
1000 Oai Id
  1. oai:frl.publisso.de:frl:6443816 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source